Tevogen Bio (NASDAQ:TVGN) Trading 6.2% Higher – Should You Buy?

Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) rose 6.2% on Friday . The stock traded as high as $10.95 and last traded at $10.47. Approximately 100,552 shares traded hands during trading, an increase of 161% from the average daily volume of 38,592 shares. The stock had previously closed at $9.86.

Wall Street Analyst Weigh In

TVGN has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Monday, April 20th. D. Boral Capital lowered shares of Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen cut shares of Tevogen Bio to a “strong sell” rating in a report on Saturday, March 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tevogen Bio currently has a consensus rating of “Reduce” and a consensus target price of $100.00.

Tevogen Bio Stock Up 6.2%

The company’s fifty day moving average is $7.24 and its two-hundred day moving average is $12.66. The stock has a market cap of $43.56 million, a price-to-earnings ratio of -2.27 and a beta of 0.14.

Tevogen Bio (NASDAQ:TVGN) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.64) by $1.03.

Institutional Trading of Tevogen Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares in the last quarter. Deutsche Bank AG raised its holdings in Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.